Radionuclide therapy of bone metastases in view of α-emitters appearance

Olgierd Chrabański

eISSN: 2081-2833
ISSN: 2081-0016

Medycyna Paliatywna/Palliative Medicine

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

2/2015
vol. 7

Send email

Copy url:

abstract:

Review paper

Radionuclide therapy of bone metastases in view of α-emitters appearance

Olgierd Chrabański

Medycyna Paliatywna 2015; 7(2): 101–105

Online publish date: 2015/08/13

View full text Get citation

Constantly increasing number of cancer patients increases at the same time a group of patients suffering from bone metastases. These patients are usually a relatively long term survival patients who require specialized care and effective pain relief. The use of radioactive isotopes such as strontium isotope 89 or samarium isotopes 153, in the treatment, can help to relieve pain of patients with metastases in the skeletal system. Recently, it is also possible to provide an alpha emitter of radium isotope 223, which extends the life of patients with prostate cancer which is hormone refractory in treatment. Common misconception is that treatment of pain with the use of radionuclides is ineffective and difficult to access. In addition, the above procedures often considered as highly specialised are implemented too late.

keywords:

Radionuclide therapy of bone metastases in view of α-emitters appearance

Olgierd Chrabański

neoplasm metastasis, bones, strontium radioisotopes, radium